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The substitution of arginine for serine at position 114 of glycoprotein E2 in several biological and
recombinant Sindbis virus mutants was shown previously to attenuate the virus for neonatal mice and also to
accelerate virus penetration into BHK cells. To further examine the genetically linked effects on both virus
penetration into cultured cells and pathogenesis in vivo, mutants containing each of 16 different amino acid
coding changes at this position were generated by site-directed mutagenesis of a full-length cDNA clone of the
Sindbis virus genome. Viable virus was recovered following transfection of RNA transcripts from 14 of the
clones. Phenotypic analysis of these virus mutants revealed that specific amino acid residues affected either the
pathogenesis or penetration phenotype independently or both phenotypes simultaneously. Thus, both the
position of a mutation within the E2 sequence and the particular amino acid encoded at that position are
important determinants of the mutant phenotypes.
Sindbis virus (SB) particles are composed of an RNA-
containing icosahedral nucleocapsid surrounded by a host-
derived lipid envelope. Protruding from the envelope are two
viral glycoproteins, El and E2, which associate in groups of
three heterodimeric spikes (8). The glycoproteins participate
in many biological activities, including virus attachment and
penetration in cell culture (4, 6, 7, 13, 14) and pathogenesis
in animals (5, 12, 15-17, 19, 20). These proteins are also
primary targets of recognition by elements of the host
immune system. In some cases, neutralizing antigenic sites
on E2 are related genetically to the virulence phenotype of
the virus (9, 14, 15, 20).
A virulence locus at codon 114 of the E2 glycoprotein gene
of SB was identified previously. Mutation at this locus from
the wild-type serine codon in SB to an arginine codon in the
SB mutant SB-RL (2, 3) altered both the in vivo pathogen-
esis phenotype of the virus and its ability to penetrate
cultured cells. SB-RL was attenuated when inoculated into
neonatal mice and displayed an accelerated rate of penetra-
tion into BHK cells. Wild-type SB was virulent and more
slowly penetrating (5, 13, 14). The effects induced by this
mutation in SB-RL were confirmed subsequently by using a
full-length cDNA clone of SB from which infectious RNA
could be transcribed in vitro (18). Two strains of virus which
were isogenic except for E2 codon 114 were constructed.
These virus recombinants exhibited the same virulence and
penetration phenotypes as the analogous biological strains
(16).
E2 residue 114 is located within a hydrophobic sequence
of 18 uncharged and nonpolar amino acids (5). One would
predict that substitution of a positively charged arginine
residue within this region could produce a structural altera-
tion sufficient to account for changes in the pathogenesis and
penetration phenotypes. However, this substitution had no
discernible effects on other growth properties of the virus,
suggesting that specific, localized changes in protein struc-
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ture and function had occurred. In this study, we have
explored functional changes associated with the substitution
of other amino acids at E2 residue 114.
An M13-derived mutagenesis vector, mpl8SBGP, con-
taining El and E2 glycoprotein gene sequences (AfllI [nu-
cleotide {nt} 7986] to SacII [nt 11484] from wild-type SB
AR339), was used as template for mutagenesis by the
technique of Kunkel et al. (10). This construct included an
engineered, silent mutation which eliminated a PstI restric-
tion site (nt 9119) within the E2 gene as a convenient marker
for sequence replacements into a full-length SB cDNA clone
(11, 18). Specific oligonucleotide primers which had been
"doped" within the sequences corresponding to E2 codon
114 were synthesized: 5'-GCGTAACGGTTNNCATAGTG
AGTA-3', 5'-GCGTAACGGTTN(A/C/T)CATAGTGAGTA-
3', and 5'-GCGTAACGGTT(G/A)AAATAGTGAGTAG-3'.
These were phosphorylated and annealed to single-stranded
uracil-containing mpl8SBGP DNA that was obtained by
propagation in the Dut- Ung- Escherichia coli strain CJ236
(10). The DNA was converted into double-stranded replica-
tive-form molecules by using Sequenase 2.0 (United States
Biochemical Corp.) as described previously (17) and trans-
formed into E. coli JM101 (Dut+ Ung+). Individual phage
clones were screened for the presence of mutations by
sequence analysis using the dideoxy chain-termination
method (1) and an E2-specific oligonucleotide, 114SEQ (5'-
TAGCTACAAAGGATAC-3', nt 8912 to 8927), as primer.
Mutations which encoded each of 15 different amino acids at
E2 codon 114 were identified and included residues of each
chemical class: polar uncharged, nonpolar uncharged, neg-
atively charged, and positively charged (Fig. 1).
Replicative-form DNA was isolated from clones contain-
ing mutations at codon 114, and restriction fragments en-
compassing E2 codon 114 (StuI [nt 8571] to BssHII [nt 9804])
were generated. These were used to replace the analogous
fragment in the full-length SB cDNA clone pTR4000 prior to
transcription in vitro. Plasmid pTR4000 was derived from
the full-length SB clone TotollOl (18) by replacement of all
structural gene sequences with the corresponding cDNA
sequences from a wild-type SB (AR339) clone (Fig. 1). The
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FIG. 1. Mutagenesis of E2 codon 114 in the SB recombinant TR4000. The schematic shows the SB genome organization (including genes
for nonstructural proteins [nsPl to nsP4], capsid [C], the two envelope glycoproteins [E2 and El], and their signal peptides [E3 and 6K]) and
the derivation of cDNA sequences in the full-length clone pTR4000. Open areas represent TotollOl sequences (18), shaded areas represent
wild-type SB sequences (16) (SpeI site [nt 5262] through SacII site [nt 11484]), and the hatched area represents the bacteriophage SP6
promoter. Mutations generated in the wild-type serine codon and the amino acid substitution encoded are indicated. The viability of the
mutants was determined following the transfection of RNA transcripts synthesized in vitro into BHK cells and is represented as follows: +,
establishment of a productive infection with cytopathic effect at both 37 and 30°C; -, no productive infection at either temperature.
fidelity of replacement with fragments containing mutated
E2 114 codons was confirmed initially by restriction analysis
(loss of the PstI site at nt 9119) and subsequently by direct
sequence analysis of RNA transcripts synthesized in vitro.
Sequence analysis was performed by the dideoxy chain-
termination method as adapted for RNA (21) and a virus
complementary-sense oligonucleotide primer, E26.5 (5'-
TTATCTTGCGGGCCA-3', nt 9007 to 9021). Full-length
pTR4000 clones that contained an altered E2 114 codon were
designated the pTR4114 class and identified by the amino
acid encoded at position 114 (Fig. 1). Plasmids were linear-
ized with XhoI and transcribed in vitro by using SP6 RNA
polymerase as described previously (16, 18). RNA tran-
scripts were transfected into BHK cells, using Lipofectin
(BRL) as described by Polo and Johnston (17), except that
components were scaled down fivefold and transfections
were done in 2 wells of a 24-well tissue culture plate. In the
cases of isoleucine, threonine, phenylalanine, arginine,
lysine, and tryptophan, two independent mutant constructs
were examined; one representative of each of the remaining
amino acid substitutions was found in the mutagenized
phage stocks.
The effect of each mutation on virus viability and growth
was determined. BHK monolayers were transfected in du-
plicate, both at 30°C and at 37°C, to identify potential
temperature-sensitive phenotypes. High specific infectivities
(comparable to that of TR4000) and cytopathic effect re-
sulted from all but two mutant clones (TR4114-P and
TR4114-H) following transfection at either 30 or 37°C (Fig.
1). For the remaining mutants, no significant differences in
the onset of cytopathic effect, the resulting virus titers, or
the specific infectivities of radiolabeled RNA transcripts
were observed (18; also data not shown). Thus, it was
unlikely that virus populations containing reversions or
compensatory mutations were being selected. The viability
of mutant viruses with such a diversity of amino acid
substitutions (with the probable exceptions of histidine and
proline) suggested a high degree of flexibility in glycoprotein
E2 in the vicinity of residue 114.
The virulence of each mutant virus strain was tested by
subcutaneous (s.c.) inoculation of 100 PFU into 1-day-old
mice (Table 1). The results were compared with those for
TR4000, the virulent parental strain (E2 Ser-114) derived
from unsubstituted pTR4000, and with those for TR4500, an
attenuated derivative of TR4000 which corresponds to the
biological mutant SB-RL (E2 Arg-114). TR4000 produced
mortality rates of 100% with average survival times (AST) of
less than 7 days. In contrast, TR4500, with arginine at E2
114, produced mortality rates of less than 20% with extended
survival times. For the experiments described below, mu-
tants characterized by a mortality rate of less than 100% or
significantly extended AST or both were considered attenu-
ated. Animals which survived inoculation of each attenuated
mutant also survived challenge at 3 to 4 weeks of age with
S.A.AR86, an adult neurovirulent strain of SB (19), con-
firming that they had been previously infected and had
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TABLE 1. Virulence of SB E2 114 mutants
Virulence for neonatal micea inoculated with:
Recombinant Amino acid encoded at 100 PFU 10 PFU
virus strain E2 114
% Mortality (no. dead! AST (days)' % Mortality (no. dead! AST
no. tested)b no. tested)b (days)'
TR4000 Ser 100 (22/22) 5.4 ± 1.1 100 (10/10) 4.5 ± 0.6
TR4500 Arg 13 (3/23) 9.7 ± 3.2d NDe
TR4114-A Ala 100 (10/10) 4.2 ± 0.8 100 (10/10) 5.3 ± 1.2
TR4114-I Ile 100 (20/20) 6.3 ± 2.2 100 (9/9) 5.6 ± 1.0
TR4114-N Asn 100 (11/11) 5.1 ± 1.0 100 (19/19) 4.5 ± 1.4
TR4114-G Gly 100 (10/10) 6.7 ± 2.4 100 (10/10) 6.3 ± 1.3
TR4114-D Asp 100 (10/10) 4.7 ± 0.8 100 (9/9) 6.0 ± 1.0
TR4114-E Glu 100 (9/9) 5.1 ± 1.4 100 (9/9) 5.8 ± 1.0
TR4114-T Thr 100 (20/20) 6.0 ± 1.3 90 (9/10) 7.4 ± 1.4
TR4114-L Leu 100 (10/10) 5.9 ± 1.4 60 (6/10) 8.3 ±
TR4114-V Val 100 (11/11) 6.7 ± 1.9 57 (4/7) 7.3 ± o.5
TR4114-Y Tyr 90 (9/10) 7.7 ± 1.0 13 (2/16) 9.0 ± 1.4d
TR4114-F Phe 85 (28/33) 7.5 ± 1.4 80 (16/20) 7.3 ±
TR4114-R Arg 18 (4/22) 9.8 ± 1.0d ND
TR4114-K Lys 5 (2/40) 11.5 ± 2.1d ND
a Virulence following s.c. inoculation of 1-day-old CD-1 mice.
b Percent mortality was calculated after a 14-day observation period.
AST ± standard deviation was calculated for animals that died.
d AST value which differs significantly from that for TR4000 (Student's t test, P < 0.001).
e ND, not determined.
mounted a protective immune response. In one case
(TR4114-V at 10 PFU), one of three animals surviving the
original infection succumbed to the S.A.AR86 challenge,
and this individual was not considered in the subsequent
analysis.
The virus strains generated by mutagenesis of E2 codon
114 displayed varied effects on virulence and appeared to
segregate into several broad groups. The first group, which
included the largest proportion of mutants, remained viru-
lent for neonatal mice, with AST similar to those found with
TR4000. It has not been established whether the underlying
pathogenesis which leads to death is identical for each of
these mutants. Another group, which included both the
lysine and arginine mutants, produced high degrees of atten-
uation, similar to that found with TR4500 and roughly
equivalent to each other. These mutants were characterized
by 50% lethal dose values greater than 106 PFU by the s.c.
route of inoculation (data not shown). A third group, which
included the mutants with phenylalanine and tyrosine resi-
dues, appeared to produce an intermediate level of attenua-
tion. The virulence of these mutants was reduced signifi-
cantly compared with that of the parental virus TR4000;
however, the degree of attenuation was substantially less
than that produced by the positively charged residues. In
addition, three other residues, including threonine, leucine,
and valine, exhibited minimal attenuation at small virus
inocula. Of the virus mutants which were attenuated by the
s.c. route of inoculation, only the lysine and arginine mu-
tants were attenuated following intracerebral inoculation
(data not shown). The variations in virulence characteristic
of the mutants likely reflect different physical effects exerted
on the hydrophobic pocket encompassing residue 114. The
presence of a strong positive charge or a large ring structure
at this position appears sufficient to induce a structural
change leading to attenuation, with positive charge possibly
more significant than size and shape constraints.
Because the amino acid substitutions with large ring
structures in their side chains constituted one group of
attenuating mutations, one would predict that if the resulting
virus was viable, a tryptophan substitution might also exhibit
a similar attenuated phenotype. In order to explore this
possibility, a specific oligonucleotide primer, 5'-GCGTAAC
GGTT1cKATAGTGAGTAG-3', which specifies tryptophan
at E2 114, was synthesized and used in mutagenesis reactions
as previously described. RNA transcribed in vitro from these
templates was shown to produce viable infectious virus as
evidenced by times until onset of cytopathic effect, virus
titers, and specific infectivities of the RNA transcripts. Fol-
lowing s.c. inoculation of the tryptophan mutant virus into
1-day-old mice, the mortality rates were 97% (38 of 39 mice;
AST = 5.9 ± 1.4 days) at a dose of 100 PFU and 33% (3 of 9
mice; AST = 8.3 + 2.1 days) at a dose of 10 PFU (data not
shown). These results were comparable to those of the
phenylalanine and tyrosine mutants and consistent with the
notion that large ring structures substituted at E2 114 pro-
duced an attenuated phenotype.
Previous studies demonstrated that the substitution of
arginine for serine at E2 residue 114 affected not only the
virulence phenotype but also virus penetration into BHK
cells (5, 13, 16). To examine further the relationships be-
tween these two phenotypes, we assessed the penetration
characteristics of each E2 114 virus mutant. Penetration was
defined as the time-dependent acquisition of resistance to
neutralization by polyclonal anti-SB antibody and was de-
termined by methods described previously as the percentage
of input virus penetrated in a 15-min period (14, 15). The E2
114 mutant viruses, regardless of their virulence in vivo,
displayed penetration values ranging from ones similar to
that of the slowly penetrating parent TR4000 to ones that
were as high as that of the rapidly penetrating mutant
TR4500 (Table 2). The tryptophan mutant generated in
subsequent experiments had penetration values within the
range of those of the phenylalanine and tyrosine mutants,
having a penetration rate of 30.5 + 12.6% (data not shown).
Previous experiments with neutralization escape mutants
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TABLE 2. Comparative penetration of SB E2 114 mutants
Recombinant virus Level of % Penetration'
strain virulencea + SD
TR4000 Vir 21.9 ± 11.0
TR4114-N Vir 25.7 ± 3.8
TR4114-F Att 32.3 ± 10.5
TR4114-L Vir 33.8 ± 13.3
TR4114-E Vir 34.5 ± 11.2
TR4114-D Vir 35.7 ± 15.9
TR4114-A Vir 37.7 ± 11.5
TR4114-Y Att 38.3 ± 6.4c
TR4114-V Vir 38.5 ± 20.2c
TR4114-G Vir 49.0 ± 17.8c
TR4500 Att 53.0 + 7.0c
TR4114-T Vir 53.3 ± 9.lc
TR4114-I Vir 55.7 ± 17.7c
TR4114-R Att 59.3 ± 8.1l
TR4114-K Att 63.0 ± 15.4c
a Virulence following s.c. inoculation of 100 PFU into 1-day-old CD-i mice
(Table 1). Vir, virulent (i.e., 100% mortality at this dose); Att, attenuated (i.e.,
less than 100% mortality at this dose).
b Values represent mean percent plaque survival after addition of anti-SB
antibody and complement 15 min postinfection, as previously described (16).
n = 13 for TR4000 and TR4500; 4 for Leu, Glu, Val, and Gly mutants; and 3
for all others.
c Value which differs significantly from that for TR4000 (Student's t test, P
< 0.01).
selected with monoclonal antibodies to the E2-c antigenic
site showed that attenuation and a rapid penetration pheno-
type were not invariably linked (14, 15). The results of the
experiments reported here clearly demonstrated that the
attenuation and penetration phenotypes, linked genetically
by the E2 arginine 114 substitution in SB-RL, depended on
the particular amino acid encoded at the E2 114 locus. Other
amino acid substitutions at E2 residue 114 altered the
pathogenesis and penetration phenotypes independently.
These data are consistent with the hypothesis that in the
vicinity of residue 114, glycoprotein E2 contains both a
penetration domain and a domain affecting pathogenesis.
The relationship between the penetration phenotype in cell
culture and the in vivo phenotype of attenuation is not likely
to be one of cause and effect. Rather, the relationship is one
in which certain substitutions at a residue common to both
domains can affect either phenotype independently or both
phenotypes simultaneously, as determined by the structural
effects of specific amino acids. In this context, mutants
having tyrosine, phenylalanine, or tryptophan at E2 114
constitute a group distinguished from lysine and arginine
mutants on the basis of the phenotypic effects of these
substitutions. It is likely that the phenotypic differences
displayed by each category of substitution are the result of a
distinctive alteration in the structure of the glycoprotein
spike.
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